Building a Playbook for Emerging Therapies in Immunology and Inflammation

Explore the transformative impact of cell and gene therapies on standards of care for immune-compromised patients.

This webinar will delve into the rapid advancements in clinical development across a variety of disease states, highlighting the parallel shifts in research landscapes, including oncology and standards of care. Learn how to enhance site readiness and patient centricity and discover the importance of early planning and data-driven decisions in the successful development of non-oncological cell and gene therapies.

In this webinar, the expert speakers will examine the swift advancements in clinical development across various disease states. The webinar will also cover strategies to boost site readiness and patient-centered approaches, in addition to the critical role of early planning and data-driven decision-making in the effective development of non-oncological cell and gene therapies.

They will also focus on the essentials of preparing for functional service provider (FSP) models, which involve defining the future operational model and comprehend the readiness requirements necessary to achieve successful integration. The key topics of this webinar include:

• Outlining a clear roadmap for structuring organizations to seamlessly integrate and succeed with FSP
• How to strategically invest in organizational structure without necessitating a complete overhaul, focusing on setting priorities and managing controllable risk variability effectively
• Employing the right implementation strategies to ensure success in adopting these advanced therapeutic modalities

Register for this webinar to understand how cell and gene therapies are revolutionizing care for immune-compromised patients, reshaping research landscapes and improving patient outcomes beyond oncology.

Speakers

Erin Finot, Vice President, Immuno-Oncology and Cell and Gene Therapies, IQVIA Biotech

Erin Finot, Vice President of Immuno-Oncology & CAGT at IQVIA Biotech leads strategic efforts to ensure high-quality services and innovative solutions for biotech sponsors. With over 20 years of experience in global clinical research and drug development, Erin’s therapeutic expertise guides sponsors through the dynamic landscape of immuno-oncology and cell and gene therapies.

Message Presenter

Jessica Knight-Perry, MD, MSc, Senior Medical Director, Strategy Lead, IQVIA Cell and Gene Therapy Center of Excellence

Jessica Knight-Perry, MD, MS, Senior Medical Director in the IQVIA Cell and Gene Therapy Center of Excellence, is a board-certified pediatric hematologist/oncologist with additional expertise in hematopoietic stem cell transplantation and delivery of cell and gene therapies. In her current position, Jessica supports the development of cell and gene therapy assets for pharmaceutical and biotech companies.

Message Presenter

Emily Smith, Director, Therapeutic Strategy, IQVIA Biotech

Emily Smith is a Therapeutic Strategy Lead at IQVIA’s Cell and Gene Therapy Center of Excellence. With over 10 years of experience, Emily specializes in trial design and feasibility, focusing on non-oncology cell and gene therapy studies. She co-leads the Cell Therapy in Autoimmune Disease Working Group, collaborating with experts to develop comprehensive strategies for complex therapies.

Message Presenter